Seeking Alpha

Immunomedics, Inc. (IMMU)

()

News & PR
Market Currents

Buzz
Twitter: IMMU

Business Intelligence
Transcripts
Events
Key Developments

Instablog posts on IMMU

FIRST COVERAGE WEEKLY SENTIMENT (October 27, 2009): Market Prepares for ‘Trick or Treat.’ by First Coverage
Sell-side comes dressed as unimpressed for Halloween.With Halloween less than a week away, it seems quite appropriate that this market is ready to play with the fears, worries and anxieties of industry professionals everywhere. Even as earnings season blew the doors off what most had... More »
October 26, 2009 • GILD, WMS, COH
Spectrum Pharmaceuticals: $50 Million Vote of Confidence or Cause for Concern by Justin M. Hall
On Friday, Spectrum Pharmaceuticals (SPPI) announced the company sold $50 million worth of common shares at $7.55. As is often the case when a company sells its shares the share price falls.Shares of SPPI closed down -4.39% to $7.18 in Friday trading.As result of this most recent offering... More »
September 18, 2009 • SPPI, ARIA, AGN
Spectrum Pharmaceuticals: Post Zevalin Approval Sales Should Ramp Up by Justin M. Hall
As many, who have followed and/or invested in Spectrum Pharmaceuticals (SPPI), know Zevalin® was finally (and thankfully) approved last Friday, September 4 by the FDA for first-line consolidation use in patients with non-Hodgkins lymphoma (NHL). PRELIMINARY FACTSZevalin is the first of... More »
September 11, 2009 • BMY, PFE, OSIP
Does IMMU's success mean HGSI's failure? by M. E. Garza
Immunomedics, Inc. (Nasdaq: IMMU) got good news yesterday. Really big news.If you're not familiar with Immunomedics, they're a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune... More »
August 28, 2009 • HGSI, IMMU
Immunomedics Inc., (IMMU) Soars Past 49 Percent on Mid-stage Study of Lupus Drug by Small Cap Network
Immunomedics Inc., (IMMU) and Belgian firm UCB Pharmaceutical collaborative tests on drug Epratuzumab show strong results in treating immune disease. Gaining 49.06% ($2.09) this morning in early trading is Immunomedics Inc., (IMMU) http://www.immunomedics.com/ which is currently trading on the... More »
August 27, 2009 • IMMU
Select Comfort (SCSS) Initial Coverage, Republic Airways (RJET) Beats Southwest and Immunomedics (IMMU) FDA Application by Small Cap Network
Select Comfort (SCSS) gets initial ‘Buy’ coverage from KeyBanc, Republic Airways (RJET) beats Southwest bid for Frontier and Immunomedics (IMMU) files FDA Application.While market buyers and sellers were both disappointed that the Consumer Price Index, the CPI, was flat for July, or... More »
August 14, 2009 • SCSS, RJET, IMMU
20 Stocks Poised to Move Higher by Justin M. Hall
Investors should use this list as starting point for their own research and analysis. WEEKLY CHART ANALYSISAs of the close on Thursday, July 30, 2009, the following stocks are technically positioned to move higher. The weekly chart analysis is based on specific weekly... More »
July 31, 2009 • ALKS, ARIA, CELG
FDA, Clinical Trial Calendars: Cancer Drug Updates from ASCO by Mike Havrilla
Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision... More »
May 31, 2009 • AZN, RHHBY.PK, OSIP
Clinical Trial Updates: Cancer Drugs in Focus as ASCO Approaches by Mike Havrilla
Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision... More »
May 17, 2009 • ALTH, CRGN, CTIC
FDA, Clinical Trial Calendar Updates: AMAG, IMMU by Mike Havrilla
Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision... More »
May 12, 2009 • AMAG, IMMU

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Immunomedics, Inc. (IMMU)

Instablog posts on IMMU

FIRST COVERAGE WEEKLY SENTIMENT (October 27, 2009): Market Prepares for ‘Trick or Treat.’ by First Coverage

Spectrum Pharmaceuticals: $50 Million Vote of Confidence or Cause for Concern by Justin M. Hall

Spectrum Pharmaceuticals: Post Zevalin Approval Sales Should Ramp Up by Justin M. Hall

Does IMMU's success mean HGSI's failure? by M. E. Garza

Immunomedics Inc., (IMMU) Soars Past 49 Percent on Mid-stage Study of Lupus Drug by Small Cap Network

Select Comfort (SCSS) Initial Coverage, Republic Airways (RJET) Beats Southwest and Immunomedics (IMMU) FDA Application by Small Cap Network

20 Stocks Poised to Move Higher by Justin M. Hall

FDA, Clinical Trial Calendars: Cancer Drug Updates from ASCO by Mike Havrilla

Clinical Trial Updates: Cancer Drugs in Focus as ASCO Approaches by Mike Havrilla

FDA, Clinical Trial Calendar Updates: AMAG, IMMU by Mike Havrilla

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers